Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery: a review of current treatment strategies

Andrew J. Jackson, Paul Coats, Douglas J. Orr, R. Paul Teenan, Roger M. Wadsworth

Research output: Contribution to journalLiterature review

3 Citations (Scopus)

Abstract

A total of 12,000 infrainguinal bypass grafts are performed annually in the United Kingdom, with outcomes suboptimal: 20% of above-knee vein grafts require intervention by 3 years. Transatlantic Inter-Society Consensus (TASC) guidelines exist on pharmacological management of peripheral vascular disease patients, however, little is recommended regarding optimum pharmacological management following revascularization to improve graft patency. The current recommendation is that all patients are on an antiplatelet agent following bypass grafting, the only intervention with significant evidence supporting use.

This article will review pharmacological strategies aimed at improving the survival of infrainguinal vein grafts and the current evidence base for their use.

LanguageEnglish
Pages562-572
Number of pages11
JournalAnnals of Vascular Surgery
Volume24
Issue number4
DOIs
Publication statusPublished - 6 May 2010

Fingerprint

Transplants
Drug Therapy
Pharmacology
Veins
Peripheral Vascular Diseases
Platelet Aggregation Inhibitors
Therapeutics
Knee
Guidelines
United Kingdom

Keywords

  • peripheral arterial-disease
  • coronary balloon angioplasty
  • muscle-cell-proliferation
  • activated protein-kinase
  • intimal hyperplasia
  • nitric-oxide
  • oral anticoagulants
  • randomized-trial
  • angiographic restenosis
  • antiplatelet therapy

Cite this

Jackson, Andrew J. ; Coats, Paul ; Orr, Douglas J. ; Teenan, R. Paul ; Wadsworth, Roger M. / Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery : a review of current treatment strategies. In: Annals of Vascular Surgery . 2010 ; Vol. 24, No. 4. pp. 562-572.
@article{36e92ca7269b4a468d53ee99fd20954d,
title = "Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery: a review of current treatment strategies",
abstract = "A total of 12,000 infrainguinal bypass grafts are performed annually in the United Kingdom, with outcomes suboptimal: 20{\%} of above-knee vein grafts require intervention by 3 years. Transatlantic Inter-Society Consensus (TASC) guidelines exist on pharmacological management of peripheral vascular disease patients, however, little is recommended regarding optimum pharmacological management following revascularization to improve graft patency. The current recommendation is that all patients are on an antiplatelet agent following bypass grafting, the only intervention with significant evidence supporting use.This article will review pharmacological strategies aimed at improving the survival of infrainguinal vein grafts and the current evidence base for their use.",
keywords = "peripheral arterial-disease, coronary balloon angioplasty, muscle-cell-proliferation, activated protein-kinase, intimal hyperplasia, nitric-oxide, oral anticoagulants, randomized-trial, angiographic restenosis, antiplatelet therapy",
author = "Jackson, {Andrew J.} and Paul Coats and Orr, {Douglas J.} and Teenan, {R. Paul} and Wadsworth, {Roger M.}",
year = "2010",
month = "5",
day = "6",
doi = "10.1016/j.avsg.2010.02.028",
language = "English",
volume = "24",
pages = "562--572",
journal = "Annals of Vascular Surgery",
issn = "0890-5096",
number = "4",

}

Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery : a review of current treatment strategies. / Jackson, Andrew J.; Coats, Paul; Orr, Douglas J.; Teenan, R. Paul; Wadsworth, Roger M.

In: Annals of Vascular Surgery , Vol. 24, No. 4, 06.05.2010, p. 562-572.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery

T2 - Annals of Vascular Surgery

AU - Jackson, Andrew J.

AU - Coats, Paul

AU - Orr, Douglas J.

AU - Teenan, R. Paul

AU - Wadsworth, Roger M.

PY - 2010/5/6

Y1 - 2010/5/6

N2 - A total of 12,000 infrainguinal bypass grafts are performed annually in the United Kingdom, with outcomes suboptimal: 20% of above-knee vein grafts require intervention by 3 years. Transatlantic Inter-Society Consensus (TASC) guidelines exist on pharmacological management of peripheral vascular disease patients, however, little is recommended regarding optimum pharmacological management following revascularization to improve graft patency. The current recommendation is that all patients are on an antiplatelet agent following bypass grafting, the only intervention with significant evidence supporting use.This article will review pharmacological strategies aimed at improving the survival of infrainguinal vein grafts and the current evidence base for their use.

AB - A total of 12,000 infrainguinal bypass grafts are performed annually in the United Kingdom, with outcomes suboptimal: 20% of above-knee vein grafts require intervention by 3 years. Transatlantic Inter-Society Consensus (TASC) guidelines exist on pharmacological management of peripheral vascular disease patients, however, little is recommended regarding optimum pharmacological management following revascularization to improve graft patency. The current recommendation is that all patients are on an antiplatelet agent following bypass grafting, the only intervention with significant evidence supporting use.This article will review pharmacological strategies aimed at improving the survival of infrainguinal vein grafts and the current evidence base for their use.

KW - peripheral arterial-disease

KW - coronary balloon angioplasty

KW - muscle-cell-proliferation

KW - activated protein-kinase

KW - intimal hyperplasia

KW - nitric-oxide

KW - oral anticoagulants

KW - randomized-trial

KW - angiographic restenosis

KW - antiplatelet therapy

U2 - 10.1016/j.avsg.2010.02.028

DO - 10.1016/j.avsg.2010.02.028

M3 - Literature review

VL - 24

SP - 562

EP - 572

JO - Annals of Vascular Surgery

JF - Annals of Vascular Surgery

SN - 0890-5096

IS - 4

ER -